Absci Reports Increased Losses and Revenue Decline, Secures $105.8M in Capital, Advances Lead Clinical Candidate ABS-201, and Details AMD Partnership
ABSI sits 41% above its 52-week low of $2.01.
Summary
Absci Corp reported increased net losses and decreased revenue in its 2025 annual report, but secured $105.8 million in capital, initiated a Phase 1/2a clinical trial for its lead candidate ABS-201 with favorable early safety, and formed a strategic partnership with AMD.
Key Events · Corporate Governance and Compliance · ABSI
-
Increased Net Loss and Revenue Decline
Absci Corp reported a net loss of $115.2 million for the year ended December 31, 2025, an increase from $103.1 million in 2024. Partner program revenue decreased by 38% to $2.8 million in 2025 from $4.5 million in 2024.
-
Significant Capital Raises in 2025
The company secured $105.8 million in net proceeds from equity issuances in 2025, including a $20.0 million private investment in public equity (PIPE) from Advanced Micro Devices, Inc. (AMD) and a $46.7 million public offering. This funding is expected to provide liquidity for at least the next 12 months.
-
Lead Candidate ABS-201 Advances to Clinic
The Phase 1/2a HEADLINE clinical trial for ABS-201, targeting androgenetic alopecia, was initiated in December 2025. The first three single ascending dose cohorts have shown favorable emerging safety data, with interim proof-of-concept data expected in the second half of 2026. A Phase 2 trial for endometriosis is planned for Q4 2026.
-
Strategic Collaboration with AMD
In January 2025, Absci entered a strategic collaboration with AMD to optimize AMD Instinct accelerators and ROCm software for its AI drug creation, further validated by AMD's $20.0 million PIPE investment at a premium over market price.
Analysis · ABSI · Industrial Applications And Services
Absci Corp's annual report reveals a challenging financial year with increased net losses and a significant drop in revenue. However, the company successfully raised substantial capital through a PIPE investment from AMD and a public offering, which is critical for its liquidity and operations for at least the next 12 months. The initiation of the Phase 1/2a clinical trial for its lead candidate, ABS-201, with favorable early safety data, and the strategic collaboration with AMD, are key positive developments for a clinical-stage biotech. The decision to seek a partner for ABS-101, despite positive early results, indicates a strategic reprioritization of resources. Investors should monitor the progress of ABS-201's clinical trials and the company's ability to manage its cash burn and secure future funding without excessive dilution.
How filings like this one have moved
In the 30 days to Sep 23, 2026, 29.1% of the 1683 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.32%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABSI was trading at $2.84 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $452.6M. The 52-week trading range was $2.01 to $5.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.